Characterization of different CTC subpopulations in non-small cell lung cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hanssen, Annkathrin ^a   Wagner, Jenny ^b   Gorges, Tobias M ^a   Taenzer, Aline ^a,c   Uzunoglu, Faik G ^a   Driemel, Christiane ^d   Stoecklein, Nikolas H ^d   Knoefel, Wolfram T ^d   Angenendt, Sebastian ^d,e   Hauch, Siegfried ^b   Atanackovic, Djordje ^a   Loges, Sonja ^a   Riethdorf, Sabine ^a   Pantel, Klaus ^a   Wikman, Harriet ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b QIAGEN Hannover GmbH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e ST VINZENZ HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPCAM PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITHELIAL CELL ADHESION MOLECULE; ERBB3 PROTEIN, HUMAN; MET PROTEIN, HUMAN; NUCLEAR PROTEIN; SCATTER FACTOR RECEPTOR; TUMOR MARKER; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TISSUE MICROARRAY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASTIC CELLS, CIRCULATING; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; TISSUE ARRAY ANALYSIS; TWIST-RELATED PROTEIN 1;

EID: 84974668173     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28010     Document Type: Article

References (35)

1. Malvezzi, M. et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 26, 779-786, doi: 10.1093/annonc/mdv001 (2015).
2. Yano, T., Okamoto, T., Fukuyama, S., Maehara, Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol 5, 1048-1054, doi: 10.5306/wjco.v5.i5.1048 (2014).
3. Joosse, S. A., Gorges, T. M., Pantel, K. Biology, detection, clinical implications of circulating tumor cells. EMBO Mol Med 7, 1-11, doi: 10.15252/emmm.201303698 (2015).
4. Alix-Panabieres, C., Pantel, K. Challenges in circulating tumour cell research. Nat Rev Cancer 14, 623-631, doi: 10.1038/nrc3820 (2014).
5. Coumans, F., Terstappen, L. Detection and Characterization of Circulating Tumor Cells by the CellSearch Approach. Methods Mol Biol 1347, 263-278, doi: 10.1007/978-1-4939-2990-0-18 (2015).
6. Bednarz-Knoll, N., Alix-Panabieres, C., Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 31, 673-687, doi: 10.1007/s10555-012-9370-z (2012).
7. Gires, O., Stoecklein, N. H. Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci 71, 4393-4402, doi: 10.1007/s00018-014-1693-1 (2014).
8. Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10, 6897-6904, doi: 10.1158/1078-0432.CCR-04-0378 (2004).
9. Hanssen, A., Loges, S., Pantel, K., Wikman, H. Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer. Front Oncol 5, 207, doi: 10.3389/fonc.2015.00207 (2015).
10. Krebs, M. G. et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29, 1556-1563, doi: 10.1200/JCO.2010.28.7045 (2011).
11. Wang, J., Wang, K., Xu, J., Huang, J., Zhang, T. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PloS one 8, e78070, doi: 10.1371/journal.pone.0078070 (2013).
12. Fina, E. et al. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer. Int J Biol Markers 0, doi: 10.5301/jbm.5000166 (2015).
13. Went, P. et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94, 128-135, doi: 10.1038/sj.bjc.6602924 (2006).
14. Isobe, K. et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res 32, 3339-3344 (2012).
15. Hirose, T. et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res 20, 131-137 (2012).
16. Somasundaram, A., Socinski, M. A., Burns, T. F. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother 15, 2693-2708, doi: 10.1517/14656566.2014.971013 (2014).
17. Zhang, L. et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5, 180ra148, doi: 10.1126/scitranslmed.3005109 (2013).
18. Bethune, G., Bethune, D., Ridgway, N., Xu, Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2, 48-51 (2010).
19. Pantel, K., Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73, 6384-6388, doi: 10.1158/0008-5472.CAN-13-2030 (2013).
20. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359, 366-377, doi: 10.1056/NEJMoa0800668 (2008).
21. Jiang, F. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7, 330-338, doi: 10.1158/1541-7786.MCR-08-0393 (2009).
22. Okudela, K. et al. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, beta-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int 62, 792-801, doi: 10.1111/pin.12019 (2012).
23. Papadaki, M. A. et al. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC cancer 14, 651, doi: 10.1186/1471-2407-14-651 (2014).
24. Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14, R15, doi: 10.1186/bcr3099 (2012).
25. Guo, L. et al. Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. Am J Pathol 178, 2357-2366, doi: 10.1016/j.ajpath.2011.01.047 (2011).
26. Vishnoi, M. et al. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep 5, 17533, doi: 10.1038/srep17533 (2015).
27. Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31, 539-544, doi: 10.1038/nbt.2576 (2013).
28. Grande, M. et al. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci 115, 4227-4236 (2002).
29. Singh, A., Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751, doi: 10.1038/onc.2010.215 (2010).
30. Goffin, J. R., Zbuk, K. Epidermal growth factor receptor: pathway, therapies, pipeline. Clin Ther 35, 1282-1303, doi: 10.1016/j. clinthera.2013.08.007 (2013).
31. Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441, doi: 10.1038/nature05474 (2007).
32. Ayoola, A., Barochia, A., Belani, K., Belani, C. P. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30, 433-446, doi: 10.3109/07357907.2012.666691 (2012).
33. Wrage, M. et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 15, 1566-1574, doi: 10.1158/1078-0432.CCR-08-2188 (2009).
34. Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13, 920-928 (2007).
35. Pantel, K. et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3, 165-173 (1994).